Ehab M. Attalla,Nashaat A. Deiab,Walaa S. Abd Elgawad. Dosimetric evaluation using the diode measurements for total skin electron therapy technique. Oncol Transl Med, 2014, 13: 328-331. |
Dosimetric evaluation using the diode measurements for total skin electron therapy technique |
|
View Full Text View/Add Comment Download reader |
KeyWord:total skin electron therapy (TSET); in vivo dosimetry; diode detector; mycosis fungoides (MF) |
Author Name | Affiliation | Ehab M. Attalla | Radiotherapy & Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt | Nashaat A. Deiab | Radiotherapy & Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt | Walaa S. Abd Elgawad | Radiotherapy & Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt |
|
Hits: 7184 |
Download times: 11583 |
Abstract: |
Objective: The purpose of this study was to present the dosimetric study and evaluation the dose delivered to the skin tumor by using diode detector with total skin electron therapy (TSET). Methods: The total skin electron irradiation (TSEI) technique was used to treat ten patients with histological confirmed mycosis fungoides according to the Stanford staging system at the Radiotherapy Department, National Cancer Institute, Cairo University, Egypt. High dose rate electron beams with low electron energy 5 MeV from a Siemens linear accelerator were used for treatment. Diodes were calibrated at TSET distance 300 cm and field size (35 x 35) cm2. Results: The result of diodes measurements showed the dose to flat surface of the body was within ±10 % from the prescribed dose. Special areas of the body such as the perineum & eyelid showed large deviation up to 30% variation from the prescription dose. Conclusion: The diode results of this study will be used as a quality assurance check for all new patients treated with TSET and to compare it to the prescribed dose delivered to the patients. It is recommends to evaluate the diodes measurements for all patients throughout the full treatment cycle and to identify individually the boost dose areas. |
Close |
|
|
|